Kewcharoen Jakrin, Ali Mohammed, Trongtorsak Angkawipa, Mekraksakit Poemlarp, Vutthikraivit Wasawat, Kanjanauthai Somsupha
University of Hawaii Internal Medicine Residency Program Honolulu, HI, USA.
Department of Internal Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn University Bangkok, Thailand.
Am J Cardiovasc Dis. 2021 Jun 15;11(3):348-359. eCollection 2021.
Admission hyperglycemia (AH) is a common finding in patients with acute coronary syndrome and has been reported to be associated with increased morbidity and mortality. Prior studies suggest that AH could be associated with reperfusion failure. We conducted a systematic review and meta-analysis to explore an association between AH and risk of reperfusion failure in patients with ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (pPCI).
Two investigators searched the databases of MEDLINE and EMBASE from inception to February 2021. Study eligibility was independently determined by two investigators and needed to demonstrate association of AH and rate of reperfusion failure, or sufficient raw data to calculate the effect size. Participants were classified into two groups corresponding to their level of admission hyperglycemia. Group 1 was defined as an AH of ≥120-150 mg/dl, and group 2 as ≥150-200 mg/dl. Data from each study were combined using the random-effects model, the generic inverse-variance method of Der Simonian and Laird. The heterogeneity of effect size was quantified using the I statistic. A sensitivity analysis was performed by omitting one study at a time. Publication bias was assessed using a funnel plot and the Egger's test. All data analyses were performed using STATA SE version 14.2.
A total of ten studies from 2008 to 2019 met eligibility criteria and were included in the final analysis. We found that AH is associated with increased risk of reperfusion failure in both group 1 (pooled OR=1.78, 95% CI: 1.35-2.33, I=63.2%, P<0.001) and group 2 (pooled OR=1.44, 95% CI: 1.14-1.82, I=57.1%, P<0.001). Sensitivity analysis showed that none of the results were significantly altered after removing one study at a time. In subgroup analysis of non-diabetic patients, we found that AH is also associated with increased risk of reperfusion failure in both group 1 (pooled OR=1.81, 95% CI: 1.29-2.54, P<0.001) and group 2 (pooled OR=1.61, 95% CI: 1.17-2.21, P<0.001). We did not perform a funnel plot or Egger's test as the number of available outcomes was insufficient to reject the assumption of funnel plot asymmetry.
Our systematic review and meta-analysis demonstrated that AH is associated with increased risk of reperfusion failure in STEMI patients undergoing pPCI, in the non-diabetic population.
入院时高血糖(AH)在急性冠状动脉综合征患者中很常见,据报道与发病率和死亡率增加有关。先前的研究表明,AH可能与再灌注失败有关。我们进行了一项系统评价和荟萃分析,以探讨AH与接受直接经皮冠状动脉介入治疗(pPCI)的ST段抬高型心肌梗死(STEMI)患者再灌注失败风险之间的关联。
两名研究者检索了MEDLINE和EMBASE数据库,检索时间从数据库建立至2021年2月。两名研究者独立确定研究的纳入标准,研究需证明AH与再灌注失败率之间的关联,或有足够的原始数据来计算效应量。参与者根据入院时高血糖水平分为两组。第1组定义为AH≥120 - 150mg/dl,第2组定义为AH≥150 - 200mg/dl。使用随机效应模型、Der Simonian和Laird的通用逆方差法合并各研究的数据。使用I统计量对效应量的异质性进行量化。通过每次剔除一项研究进行敏感性分析。使用漏斗图和Egger检验评估发表偏倚。所有数据分析均使用STATA SE 14.2版本进行。
共有2008年至2019年的10项研究符合纳入标准并纳入最终分析。我们发现,在第1组(合并OR = 1.78,95%CI:1.35 - 2.33,I = 63.2%,P < 0.001)和第2组(合并OR = 1.44,95%CI:1.14 - 1.82,I = 57.1%,P < 0.001)中,AH均与再灌注失败风险增加有关。敏感性分析表明,每次剔除一项研究后,结果均无显著改变。在非糖尿病患者的亚组分析中,我们发现第1组(合并OR = 1.81,95%CI:1.29 - 2.54,P < 0.001)和第2组(合并OR = 1.61,95%CI:1.17 - 2.21,P < 0.001)中,AH也均与再灌注失败风险增加有关。由于可用结果数量不足以拒绝漏斗图不对称的假设,我们未进行漏斗图或Egger检验。
我们的系统评价和荟萃分析表明,在接受pPCI的STEMI患者的非糖尿病人群中,AH与再灌注失败风险增加有关。